Method for inhibiting reperfusion injury using antibodies to P-selectin glycoprotein ligand
US6506382B2 · kind B2 · utility
8Cited by
22References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 29, 2001 |
| Grant date | Jan 14, 2003 |
| Priority date | — |
| Expiry date | Oct 29, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3H]glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.